Zed Zha, MD, FAAFP

Safety Protocols With JAK Inhibitors

Video content above in prompted by the following:

Discuss the Measure Up 1 and 2 studies (upadacitinib) (Simpson 2022). Do you see similar results in patients who take upadacitinib in your practice? When do you recommend this treatment?

At 52 weeks, 82.0% and 79.1% of patients taking 15 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2 respectively.

At 52 weeks, 84.9% and 84.3% of patients taking 30 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2, respectively.

The most common AEs were acne, cough, headache, herpes zoster, and creatine kinase elevation

4.5% of patients taking 15 mg upadacitinib withdrew due to AEs.

7.2% of patients taking 30 mg upadacitinib withdrew due to AEs.

Videos

Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.

Rapid Efficacy and Safety Considerations With the Use of JAK Inhibitors in Atopic Dermatitis Care

How have JAK inhibitors (upadacitinib, abrocitinib, baricitinib) changed the treatment of moderate to severe atopic dermatitis, and in what ways to they differ from traditional biologics in terms of administration, safety, and efficacy?

Panelists discuss how Janus kinase (JAK) inhibitors such as upadacitinib, abrocitinib, and baricitinib offer rapid, oral treatment for moderate to severe atopic dermatitis, differing from injectable biologics in administration, broader immunosuppression, and risk of adverse events like thromboembolism. They provide effective symptom control but require safety monitoring.

ECZTEND 2-Year Interim Findings: Takeaways and Considerations

Based on the 2-year interim findings from the ECZTEND study (tralokinumab) (Blauvelt 2022), in what circumstances would you consider tralokinumab?

Of the 291 subjects who remained in the trial for 2 years, 82.5% achieved EASI-75, and 59.8% achieved EASI-90.

In the 1-year safety study, the most common AEs were upper respiratory tract infections, atopic dermatitis, headache, and conjunctivitis.

Panelists discuss how the 2-year ECZTEND study found tralokinumab effective for atopic dermatitis, with 82.5% achieving EASI-75 and 59.8%, EASI-90. Common adverse effects (AEs) included upper respiratory tract infections, dermatitis, headache, and conjunctivitis. The treatment-emergent adverse event (TEAE) withdrawal rate was 1.6%.

LIBERTY AD Open-Label Extension Analysis: Takeaways and Considerations

Can you discuss the notable findings from the LIBERTY AD OLE study (Beck 2024) and how they are relevant to you and your practice?

Of the 326 subjects who remained in the trial for 260 weeks, 96.9% achieved EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90.

Most common AEs were nasopharyngitis, worsening AD, upper respiratory tract infection, herpes viral infections, and conjunctivitis

101/2677 (3.8%) of patients in the safety analysis set withdrew due to TEAEs.

Panelists discuss how The LIBERTY AD OLE study (Beck 2024) showed sustained efficacy of treatment in atopic dermatitis, with 96.9% achieving EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90 over 260 weeks. Common adverse events (AEs) included nasopharyngitis, atopic dermatitis (AD) worsening, upper respiratory tract infections, herpes infections, and conjunctivitis. Treatment-emergent adverse event (TEAE)–related withdrawal was 3.8%.

Zed Zha, MD, FAAFP

Articles